Meeting News CoverageVideo

VIDEO: WATS3D biopsy improves detection of Barrett's esophagus-associated high-grade dysplasia, cancer

WASHINGTON — Michael S. Smith, MD, from Temple University School of Medicine in Philadelphia, discusses his study presented at DDW 2015 demonstrating increased detection of Barrett’s esophagus-associated high-grade dysplasia or cancer using wide-area trans-epithelial sampling (WATS3D, CDx Diagnostics) in conjunction with four-quadrant biopsies.

“Our current method of endoscopic surveillance includes taking four-quadrant biopsies – the Seattle protocol – which still leaves about 94% to 96% of the esophageal mucosa unsampled, and so we’re probably missing a lot of disease that’s either residual or recurrent and just not visualized on endoscopic evaluation,” Smith said. “Our team looked at using an adjunctive technology to forceps biopsies, trans-epithelial brush biopsy specimens with the WATS3D system, to see if we could improve the detection in the post-ablation setting of intestinal metaplasia, dysplasia and neoplasia.”

Disclosure: Smith reports financial relationships with Covidien, CSA Medical, CDx Diagnostics, Ninepoint Medical and Wolters Kluwer Health.

WASHINGTON — Michael S. Smith, MD, from Temple University School of Medicine in Philadelphia, discusses his study presented at DDW 2015 demonstrating increased detection of Barrett’s esophagus-associated high-grade dysplasia or cancer using wide-area trans-epithelial sampling (WATS3D, CDx Diagnostics) in conjunction with four-quadrant biopsies.

“Our current method of endoscopic surveillance includes taking four-quadrant biopsies – the Seattle protocol – which still leaves about 94% to 96% of the esophageal mucosa unsampled, and so we’re probably missing a lot of disease that’s either residual or recurrent and just not visualized on endoscopic evaluation,” Smith said. “Our team looked at using an adjunctive technology to forceps biopsies, trans-epithelial brush biopsy specimens with the WATS3D system, to see if we could improve the detection in the post-ablation setting of intestinal metaplasia, dysplasia and neoplasia.”

Disclosure: Smith reports financial relationships with Covidien, CSA Medical, CDx Diagnostics, Ninepoint Medical and Wolters Kluwer Health.

    See more from Digestive Disease Week